Download Supplemental Data

1
Tables 1 and 2 References
2
3
1.
Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, et al. miR-205
4
Exerts tumor-suppressive functions in human prostate through down-regulation of
5
protein kinase Cepsilon. Cancer Res 2009;69:2287-95.
6
2.
7
8
microRNA expression in human prostate cancer. Oncogene 2008;27:1788-93.
3.
9
10
Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of
Pesta M, Klecka J, Kulda V, Topolcan O, Hora M, Eret V, et al. Importance of miR20a expression in prostate cancer tissue. Anticancer Res 2010;30:3579-83.
4.
Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, et al.
11
Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma.
12
Int J Cancer 2010;126:1166-76.
13
5.
Szczyrba J, Loprich E, Wach S, Jung V, Unteregger G, Barth S, et al. The microRNA
14
profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res
15
2010;8:529-38.
16
6.
Avgeris M, Stravodimos K, Fragoulis EG, Scorilas A. The loss of the tumour-
17
suppressor miR-145 results in the shorter disease-free survival of prostate cancer
18
patients. Br J Cancer 2013;108:2573-81.
19
7.
Carlsson J, Davidsson S, Helenius G, Karlsson M, Lubovac Z, Andren O, et al. A
20
miRNA expression signature that separates between normal and malignant prostate
21
tissues. Cancer Cell Int 2011;11:14.
22
8.
Fuse M, Kojima S, Enokida H, Chiyomaru T, Yoshino H, Nohata N, et al. Tumor
23
suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based
24
on microRNA expression signature in prostate cancer. J Hum Genet 2012;57:691-9.
1
25
9.
Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJ, Moller S, Trapman J, et
26
al. Diagnostic and prognostic signatures from the small non-coding RNA
27
transcriptome in prostate cancer. Oncogene 2012;31:978-91.
28
10.
Wach S, Nolte E, Szczyrba J, Stohr R, Hartmann A, Orntoft T, et al. MicroRNA
29
profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J
30
Cancer 2012;130:611-21.
31
11.
Hart M, Nolte E, Wach S, Szczyrba J, Taubert H, Rau TT, et al. Comparative
32
microRNA profiling of prostate carcinomas with increasing tumor stage by deep
33
sequencing. Mol Cancer Res 2014;12:250-63.
34
12.
He HC, Han ZD, Dai QS, Ling XH, Fu X, Lin ZY, et al. Global analysis of the
35
differentially expressed miRNAs of prostate cancer in Chinese patients. BMC
36
Genomics 2013;14:757.
37
13.
Hulf T, Sibbritt T, Wiklund ED, Patterson K, Song JZ, Stirzaker C, et al. Epigenetic-
38
induced repression of microRNA-205 is associated with MED1 activation and a
39
poorer prognosis in localized prostate cancer. Oncogene 2013;32:2891-9.
40
14.
Larne O, Martens-Uzunova E, Hagman Z, Edsjo A, Lippolis G, den Berg MS, et al.
41
miQ--a novel microRNA based diagnostic and prognostic tool for prostate cancer. Int
42
J Cancer 2013;132:2867-75.
43
15.
Srivastava A, Goldberger H, Dimtchev A, Ramalinga M, Chijioke J, Marian C, et al.
44
MicroRNA profiling in prostate cancer--the diagnostic potential of urinary miR-205
45
and miR-214. PLoS One 2013;8:e76994.
46
16.
Tsuchiyama K, Ito H, Taga M, Naganuma S, Oshinoya Y, Nagano K, et al.
47
Expression of microRNAs associated with Gleason grading system in prostate cancer:
48
miR-182-5p is a useful marker for high grade prostate cancer. Prostate 2013;73:827-
49
34.
2
50
17.
Gonzales JC, Fink LM, Goodman OB, Jr., Symanowski JT, Vogelzang NJ, Ward DC.
51
Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate
52
dehydrogenase, and prostate-specific antigen for determining treatment response in
53
patients with metastatic prostate cancer. Clin Genitourin Cancer 2011;9:39-45.
54
18.
Goto Y, Kojima S, Nishikawa R, Kurozumi A, Kato M, Enokida H, et al. MicroRNA
55
expression signature of castration-resistant prostate cancer: the microRNA-221/222
56
cluster functions as a tumour suppressor and disease progression marker. Br J Cancer
57
2015;113:1055-65.
58
19.
Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stoppler H, et al. Microfluidic-
59
based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures
60
in the sera of prostate cancer patients. Cancer Res 2011;71:550-60.
61
20.
62
63
Zheng C, Yinghao S, Li J. MiR-221 expression affects invasion potential of human
prostate carcinoma cell lines by targeting DVL2. Med Oncol 2012;29:815-22.
21.
Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, et al. Changes
64
in circulating microRNA levels associated with prostate cancer. Br J Cancer
65
2012;106:768-74.
66
22.
Farina NH, Wood ME, Perrapato SD, Francklyn CS, Stein GS, Stein JL, Lian JB.
67
Standardizing analysis of circulating microRNA: clinical and biological relevance. J
68
Cell Biochem 2014;115:805-11.
69
23.
Haj-Ahmad TA, Abdalla MA, Haj-Ahmad Y. Potential Urinary Protein Biomarker
70
Candidates for the Accurate Detection of Prostate Cancer among Benign Prostatic
71
Hyperplasia Patients. J Cancer 2014;5:103-14.
72
24.
Haldrup C, Kosaka N, Ochiya T, Borre M, Hoyer S, Orntoft TF, Sorensen KD.
73
Profiling of circulating microRNAs for prostate cancer biomarker discovery. Drug
74
Deliv Transl Res 2014;4:19-30.
3
75
25.
Westermann AM, Schmidt D, Holdenrieder S, Moritz R, Semjonow A, Schmidt M, et
76
al. Serum microRNAs as biomarkers in patients undergoing prostate biopsy: results
77
from a prospective multi-center study. Anticancer Res 2014;34:665-9.
78
26.
Kachakova D, Mitkova A, Popov E, Popov I, Vlahova A, Dikov T, et al.
79
Combinations of serum prostate-specific antigen and plasma expression levels of let-
80
7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for
81
prostate cancer. DNA Cell Biol 2015;34:189-200.
82
27.
Korzeniewski N, Tosev G, Pahernik S, Hadaschik B, Hohenfellner M, Duensing S.
83
Identification of cell-free microRNAs in the urine of patients with prostate cancer.
84
Urol Oncol 2015;33:16.e7-22.
85
28.
Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, et al. Genomic
86
profiling of microRNA and messenger RNA reveals deregulated microRNA
87
expression in prostate cancer. Cancer Res 2008;68:6162-70.
88
29.
Jalava SE, Urbanucci A, Latonen L, Waltering KK, Sahu B, Janne OA, et al.
89
Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant
90
prostate cancer. Oncogene 2012;31:4460-71.
91
30.
92
93
Mavridis K, Stravodimos K, Scorilas A. Downregulation and prognostic performance
of microRNA 224 expression in prostate cancer. Clin Chem 2013;59:261-9.
31.
Peng X, Guo W, Liu T, Wang X, Tu X, Xiong D, et al. Identification of miRs-143 and
94
-145 that is associated with bone metastasis of prostate cancer and involved in the
95
regulation of EMT. PLoS One 2011;6:e20341.
96
32.
Schubert M, Spahn M, Kneitz S, Scholz CJ, Joniau S, Stroebel P, et al. Distinct
97
microRNA expression profile in prostate cancer patients with early clinical failure and
98
the impact of let-7 as prognostic marker in high-risk prostate cancer. PLoS One
99
2013;8:e65064.
4
100
33.
101
102
Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, et al. MicroRNA profile
analysis of human prostate cancers. Cancer Gene Ther 2009;16:206-16.
34.
Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, et al. Circulating
103
miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer
104
2011;128:608-16.
105
35.
Karatas OF, Guzel E, Suer I, Ekici ID, Caskurlu T, Creighton CJ, et al. miR-1 and
106
miR-133b are differentially expressed in patients with recurrent prostate cancer. PLoS
107
One 2014;9:e98675.
108
36.
Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, Ellinger J.
109
Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology
110
2011;77:1265 e9-16.
111
37.
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL,
112
et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc
113
Natl Acad Sci U S A 2008;105:10513-8.
114
38.
Scaravilli M, Porkka KP, Brofeldt A, Annala M, Tammela TL, Jenster GW, et al.
115
MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets
116
MYCBP2. Prostate 2015;75:798-805.
117
39.
Yaman Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay
118
N, Gezer U. Investigation of miR-21, miR-141, and miR-221 in blood circulation of
119
patients with prostate cancer. Tumour Biol 2011;32:583-8.
120
40.
Chen ZH, Zhang GL, Li HR, Luo JD, Li ZX, Chen GM, Yang J. A panel of five
121
circulating microRNAs as potential biomarkers for prostate cancer. Prostate
122
2012;72:1443-52.
5
123
41.
Selth LA, Townley S, Gillis JL, Ochnik AM, Murti K, Macfarlane RJ, et al.
124
Discovery of circulating microRNAs associated with human prostate cancer using a
125
mouse model of disease. Int J Cancer 2012;131:652-61.
126
42.
Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ, Benson MC, Santella RM.
127
Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer.
128
Prostate 2012;72:1469-77.
129
43.
Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, Dai B, et al. Serum miRNA-21:
130
elevated levels in patients with metastatic hormone-refractory prostate cancer and
131
potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate
132
2011;71:326-31.
133
44.
Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chery L, Siddiqui J, et al. Circulating
134
microRNA profiling identifies a subset of metastatic prostate cancer patients with
135
evidence of cancer-associated hypoxia. PLoS One 2013;8:e69239.
136
45.
Guzel E, Karatas OF, Semercioz A, Ekici S, Aykan S, Yentur S, et al. Identification
137
of microRNAs differentially expressed in prostatic secretions of patients with prostate
138
cancer. Int J Cancer 2015;136:875-9.
139
46.
Kelly BD, Miller N, Sweeney KJ, Durkan GC, Rogers E, Walsh K, Kerin MJ. A
140
Circulating MicroRNA Signature as a Biomarker for Prostate Cancer in a High Risk
141
Group. J Clin Med 2015;4:1369-79.
142
47.
Lewis H, Lance R, Troyer D, Beydoun H, Hadley M, Orians J, et al. miR-888 is an
143
expressed prostatic secretions-derived microRNA that promotes prostate cell growth
144
and migration. Cell Cycle 2014;13:227-39.
145
48.
Mihelich BL, Maranville JC, Nolley R, Peehl DM, Nonn L. Elevated serum
146
microRNA levels associate with absence of high-grade prostate cancer in a
147
retrospective cohort. PLoS One 2015;10:e0124245.
6
148
49.
Nguyen HC, Xie W, Yang M, Hsieh CL, Drouin S, Lee GS, Kantoff PW. Expression
149
differences of circulating microRNAs in metastatic castration resistant prostate cancer
150
and low-risk, localized prostate cancer. Prostate 2013;73:346-54.
151
50.
Selth LA, Townley SL, Bert AG, Stricker PD, Sutherland PD, Horvath LG, et al.
152
Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br
153
J Cancer 2013;109:641-50.
154
51.
Wang J, Huang SK, Zhao M, Yang M, Zhong JL, Gu YY, et al. Identification of a
155
circulating microRNA signature for colorectal cancer detection. PLoS One
156
2014;9:e87451.
157
52.
Watahiki A, Macfarlane RJ, Gleave ME, Crea F, Wang Y, Helgason CD, Chi KN.
158
Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic
159
prostate cancer. Int J Mol Sci 2013;14:7757-70.
7